SCM
NVCT icon

Sterling Capital Management’s Nuvectis Pharma NVCT Stock Holding History

Sterling Capital Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$773 Buy
100
+16
+19% +$137 ﹤0.01% 3113
2025
Q4 		$634 Buy
84
+53
+171% +$346 ﹤0.01% 3175
2025
Q3 		$187 Hold
31
– – ﹤0.01% 3213
2025
Q2 		$232 Buy
+31
New +$281 ﹤0.01% 3227

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sterling Capital Management's NVCT Position: Q1 2026 in Review

Sterling Capital Management increased its Nuvectis Pharma (NVCT) stake by 19% in Q1 2026, buying an estimated $137 and bringing the position to 100 shares worth $773. The position accounts for ﹤0.01% of the portfolio, ranked #3113.

Sterling Capital Management first reported a position in NVCT in Q2 2025 and has held it in 4 quarters since. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Sterling Capital Management held 100 shares of Nuvectis Pharma worth $773 as of Q1 2026.
  • Sterling Capital Management bought 16 Nuvectis Pharma shares in Q1 2026, an estimated $137.
  • Nuvectis Pharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #3113 holding.
  • Sterling Capital Management first reported a position in Nuvectis Pharma in Q2 2025 and has held it in 4 quarters since.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.